The metabolic effects of a twenty eight days add-on steviosides supplementation in type 2 diabetes mellitus patients
Mireille Claudia Bokam Abeng1,&, Jean-Claude Njabou Katte2,
Laure Kamguia1, Hélène Ornella Ondoa Bongha1, Jean Claude
Nganou Mbanya3, Eugene Sobngwi3
1Department of Internal Medicine, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Cameroon, 2Department of public health, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Cameroon, 3National Obesity Center, Yaoundé Central Hospital and Department of Internal Medicine, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon
Mireille Claudia Bokam Abeng, Department of Internal Medicine, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Cameroon
steviosides are natural sweeteners from Stevia rebaudiana Bertoni, with potential health benefits. However, scientific evidences are sparse on their metabolic effects in human. We aimed to evaluate the effects of Rebaudioside A on glucose metabolism and lipid profile in type 2 diabetic mellitus (T2DM) patients.
we carried out a non-randomized clinical trial at the National Obesity Center of the Yaoundé Central Hospital.A total of 22 patients were included in the trial, 15 patients received an add-on supplementation of 240 mg of Stevia within 28 days on their habitual anti-diabetic treatment and 7 well controlled T2DM patients on oral antidiabetic treatment were used as controls. A standard mixed meal tolerance test was performed at baseline and after 28 days in both groups. Blood glucose and C peptide concentrations were measured.
twenty two patients (15 males and 7 females) were included in our study with
a median age of 59 [52.5-62.5] years, a duration of diabetes of 5.5 [4.6-6.0]
years.After 28 days, glycemic response to the mixed meal in the test and
control groups was [5,3(4,8-6,4) mmol/l vs 7,1(5,8-7,8); p = 0,08] at T0,
[6,3[5,6-6,8] vs 5,8 [5,2-6,8]; p = 0.09] at T30, [6,5 [5,9-7,0] vs 5,3[4,8-6,4];
p = 0.001] at
T90 and [5,3[4,5-6,4] vs 6,3(5,6-7,0) mmol/l; p = 0.11] at T120. The AUC
significantly lower compared to the control group [682, 5(616,7-739,2) vs
724(675,0-847,7); p = 0,03)]. Insulin secretion was improved by 34.4% with
a significant increase
in the AUC compared to controls [9,6[8,7-1,3] vs 8,9(5,4-9,9) nmol/l/120
min; p = 0,02]. C-peptide and glucose disposition indicesincreased significantly
(p = 0.03). Triglycerides and LDL-Cholesterol reduced significantly by 37.5%
and 16% respectively (p = 0.02) after intervention.
steviosides improved post-prandial glucose by increasing insulin secretion and sensitivity and improve lipid profile in these patients. Steviosides could be considered as potential supplements in the treatment of T2DM.